Most patients with FBXW7 mutations had limited benefit from mTOR based therapies; however, studying mTOR inhibitors in cancers lacking simultaneous molecular abnormalities as well as describing functional consequences of specific FBXW7 mutation subtypes warrants further investigation. Here, FBXW7 is linked to cancer.